Highmark Medicare Services - A CMS Contractor - ISO 9001:2000 Certified
Basic Search >
 
NOTE: This is a PREVIOUS VERSION. A more current version of this document is available.

Contractor Information

Contractor Name:

Highmark Medicare Services

Contractor Number:

12102, 12202, 12302, 12501, 12301, 12201

Contractor Type:

MAC Part A & B

LCD Information

LCD Database ID Number

L27535

LCD Title

Transesophageal Echocardiography (TEE)

Contractor’s Determination Number

L27535

AMA CPT/ADA CDT Copyright Statement

CPT codes, descriptions and other data only are copyright 2007 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply.

CMS National Coverage Policy

Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.

Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.

Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider for any claim that lacks the necessary information to process the claim.

CMS Manual System, IOM Pub. 100-03, Medicare National Coverage Determinations (NCDs) Manual, Section 220.5.

 

 

Primary Geographic Jurisdiction

Pennsylvania, Maryland, District of Columbia, Delaware

Oversight Region

Central Office

Original Determination Effective Date

For services performed on or after 07/11/2008

Original Determination Ending Date

N/A

Revision Effective Date

For services performed on or after 08/01/2008

Revision Ending Date

08/31/2008

Indications and Limitations of Coverage and/or Medical Necessity

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

NOTE: This LCD applies only to the diagnostic imaging uses of Transesophageal Echocardiography (TEE), not to the monitoring of cardiac output. For information about the monitoring of cardiac output, please see CMS NCD 220.5.

Cardiac ultrasound provides structural, functional and hemodynamic information. It can also provide anatomic information pertaining to the proximal great vessels (major arteries and vessels near the heart). The basic transesophageal echocardiography (TEE) equipment is a two-dimensional doppler color flow imaging system to which a transesophageal echocardiogram transducer can be attached. The TEE transducer is a modification of a conventional endoscope. This bi-plane or multi-plane transducer is capable of high resolution imaging, colorflow, pulsewave, and continuous wave doppler. The instrument is placed in a manner similar to the placement of the flexible endoscopic gastroscope.

TEE is not usually medically necessary when a technically adequate normal transthoracic echocardiography (TTE) has been performed. If TTE is technically inadequate, provides incomplete information, or demonstrates pathology but does not provide adequate data for definitive therapeutic decision, TEE is appropriately considered. The information TEE is expected to provide should significantly augment that obtained by TTE and contribute to clinically relevant management decisions (alter therapy).

Significant esophageal pathology (tumor, stenosis, varices, diverticula, history of dysphagia, recent esophageal operation, upper GI bleed) may be considered contraindications. The anticipated benefits must clearly exceed any potential risk.

Coverage for TEE is allowed and indicated in the following situations: When TTE has not established the diagnosis, or in a patient where TTE is felt not to give adequate information (e.g., as in extreme obesity, severe COPD, chest deformity, inadequate or incomplete visualization of the left atrium and left atrial appendage in patients with prosthetic material, and inadequate visualization of the atrial septum for making the diagnosis of patent foramen ovale).

A TEE may be performed as an initial test in the following scenarios: There is suspected acute aortic pathology including dissection or transection; for guidance of percutaneous non coronary cardiac interventions (e.g., radiofrequency ablation of atrial arrhythmias, alcohol septal ablation, percutaneous mitral valvuloplasty, atrial occluder device deployment); to determine the mechanism of valve regurgitation and/or suitability for valve repair; to diagnose or subsequently manage suspected endocarditis with moderate or high pre-test probability of the disease; persistent fever with an intracardiac device; or for clinical decision making, including possible cardioversion or radiofrequency ablation of atrial flutter or atrial fibrillation when anticoagulation alone is not already planned.

A. Native and Prosthetic Valvular Heart Disease

Native valvular heart disease in the absence of proven or suspected endocarditis may be appropriately assessed by TTE. It is rarely medically necessary to complement TTE with TEE. TTE provides a noninvasive assessment of native valve functional anatomy and ventricular adaptation and function. When TTE is technically inadequate, a TEE may provide additional useful clinical information. Serial assessment by relatively invasive TEE is not as ideal as serial assessment by a noninvasive TTE. Prior to possible valve surgical repair, TEE is useful to further assess the mechanism and severity of disease and the extent of surgery required. Prior to elective percutaneous balloon mitral valvuloplasty a TEE is needed to exclude the presence of left atrial thrombus and it may be useful as a guide to the procedure.

In most patients with valvular prostheses TTE provides diagnostic functional information and a noninvasive serial follow-up. TEE is appropriately considered when TTE results are inconclusive, and/or the left atrium must be visualized (the left atrium is not visible with TTE). TEE is not routinely indicated in all patients with prosthetic valves.

B. Bacterial Endocarditis

When endocarditis is established or the suspicion of endocarditis is high (persistent febrile state, negative cultures, pre-existent valvular pathology), TEE is considered the standard of care. Bacterial endocarditis is a rare diagnosis that carries a high mortality rate (10-20%). TEE may define small vegetative masses and more completely evaluate local complications (e.g., ring abscesses, aneurysm, fistulae).

C. Source of Embolism

In general, TTE can reliably diagnose or exclude evidence of potentially embolic material located in a ventricle. In patients with cardiac pathology associated with a high incidence of thromboembolism (valvular heart disease, arrhythmias - especially atrial fibrillation, cardiomyopathies, other causes of ventricular dysfunction), the additional information provided by TEE should be of therapeutic relevance before the patient is subjected to TEE. Transesophageal echocardiogram to search for a cardiac source of embolization is appropriate for certain patients with a negative transthoracic echocardiogram. In addition, proceeding directly to TEE may be justified in certain patient populations. In such cases the medical record should indicate the reason for proceeding directly to a TEE.

D. Cardiac and Pericardiac Masses

TTE and TEE have comparable sensitivity in the assessment of right heart masses. TEE provides more detail of left atrial masses and may provide therapeutic direction (cystic vs. solid, attachment, infiltration). When cardiac mass lesions are suspect, TEE can be an integral part of the diagnostic workup and management strategy.

E. Aortic Pathological Conditions

TEE has become an established rapid and reliable tool for the diagnosis and definition of aortic dissection and aneurysm. In suspected aortic dissection, the application of bedside biplane or multiplane TEE is frequently considered the diagnostic study "of choice."

Aortic ulceration, atherosclerotic plaque and mural thrombotic material are identified by TEE with increasing frequency particularly in older patient populations. A causative relationship between these findings and embolic events is being considered. At present, TEE investigation for this pathology cannot be considered routine. If embolic episodes are repetitive, and focused aortic surgical intervention is contemplated, TEE to search for and characterize remediable aortic lesions may be appropriate.

F. Critically Ill Patients

There is a role of echocardiography in the management of the critically ill patient. When TTE fails to provide adequate visualization, or TTE is contraindicated (e.g., chest trauma), TEE may provide diagnostic information and help guide therapy. Examples where TEE may be useful: assessment of complications of myocardial infarction, hypotension, persistent hypoxemia in patients suspected of having a right-to-left shunt, patients in shock, and brain-dead patients being considered as cardiac donors.

G. Congenital Heart Disease

In children and smaller adults TTE provides accurate anatomic definition of congenital heart diseases. In adults and postoperative patients, TEE may be appropriate for complications of congenital heart surgery, visualization of shunt flow across atrial septal defects, guidance of a clam-shell device to close atrial septal defects, diagnosis of cor triatriatum, and detection of pulmonary valve abnormalities. When TTE is technically inadequate or anatomic definition is incomplete TEE may be considered medically necessary.

H. Intraoperative Use

The interpretation of TEE during surgery is covered only when the surgeon or other physician has requested echocardiography for a specific diagnostic reason (e.g., determination of proper valve placement, assessment of the adequacy of valvuloplasty or revascularization, placement of shunts or other devices, assessment of ventricular function, assessment of vascular integrity, or detection of intravascular air). To be a covered service TEE must include a complete interpretation/report by the performing physician. Only one interpretation will be covered per operative session.

I. Cardioversion

TEE is used for the evaluation of patients with atrial fibrillation/flutter to facilitate clinical decision making with regards to anticoagulation and/or cardioversion and/or radiofrequency ablation. However, when anticoagulants are considered integral to the cardioversion and there is no contraindication to their use, incremental therapeutic information provided by routine TEE has not been demonstrated.

Echo contrast agents will be reimbursed for echocardiography enhancement when a conventional study echocardiogram has failed to opacify the left ventricle. A contrast agent is considered medically necessary when it is used to improve the delineation of the left ventricular endocardial borders. This is especially applicable during the performance of exercise echocardiographic stress testing.

The accuracy of cardiac ultrasound depends on the knowledge, skill and experience of the sonographer and physician. Sonographers who perform or supervise the studies must be capable of demonstrating training and experience specific to the study performed and maintain documentation for postpayment audit. Physicians who perform, supervise, and/or interpret the studies must be capable of demonstrating training and experience specific to the study performed or interpreted and maintain documentation for postpayment audit. A physician or a sonographer may personally perform cardiac ultrasound procedures. When a physician employs auxiliary personnel to assist him/her in rendering ultrasound procedures, the services of such personnel are considered "incident to" the physician's service. All guidelines set forth by CMS regarding "incident to" must be met.

Coverage Topic

Diagnostic Tests and X-Rays, Outpatient Hospital Services

Coding Information

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

11x

Hospital-inpatient (including Part A)

12x

Hospital-inpatient or home health visits (Part B only)

13x

Hospital-outpatient (HHA-A also) (under OPPS 13X must be used for ASC claims submitted for OPPS payment -- eff. 7/00)

83x

Special facility or ASC surgery-ambulatory surgical center (Discontinued for Hospitals Subject to Outpatient PPS; hospitals must use 13X for ASC claims submitted for OPPS payment -- eff. 7/00)

85x

Special facility or ASC surgery-rural primary care hospital (eff 10/94)

 

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

0480

Cardiology-general classification

0483

Cardiology-Echocardiology

0636

Drugs requiring specific identification-detailed coding (eff 3/92)

 

CPT/HCPCS Codes

Italicized and/or quoted material is excerpted from the American Medical Association, Current Procedural Terminology (CPT) codes.

Hospitals should use guidelines and descriptors associated with the applicable Level I CPT code(s) to bill for echocardiograms without contrast.

93312

ECHOCARDIOGRAPHY, TRANSESOPHAGEAL, REAL TIME WITH IMAGE DOCUMENTATION (2D) (WITH OR WITHOUT M-MODE RECORDING); INCLUDING PROBE PLACEMENT, IMAGE ACQUISITION, INTERPRETATION AND REPORT

93313

ECHOCARDIOGRAPHY, TRANSESOPHAGEAL, REAL TIME WITH IMAGE DOCUMENTATION (2D) (WITH OR WITHOUT M-MODE RECORDING); PLACEMENT OF TRANSESOPHAGEAL PROBE ONLY

93314

ECHOCARDIOGRAPHY, TRANSESOPHAGEAL, REAL TIME WITH IMAGE DOCUMENTATION (2D) (WITH OR WITHOUT M-MODE RECORDING); IMAGE ACQUISITION, INTERPRETATION AND REPORT ONLY

93315

TRANSESOPHAGEAL ECHOCARDIOGRAPHY FOR CONGENITAL CARDIAC ANOMALIES; INCLUDING PROBE PLACEMENT, IMAGE ACQUISITION, INTERPRETATION AND REPORT

93316

TRANSESOPHAGEAL ECHOCARDIOGRAPHY FOR CONGENITAL CARDIAC ANOMALIES; PLACEMENT OF TRANSESOPHAGEAL PROBE ONLY

93317

TRANSESOPHAGEAL ECHOCARDIOGRAPHY FOR CONGENITAL CARDIAC ANOMALIES; IMAGE ACQUISITION, INTERPRETATION AND REPORT ONLY

93320

DOPPLER ECHOCARDIOGRAPHY, PULSED WAVE AND/OR CONTINUOUS WAVE WITH SPECTRAL DISPLAY (LIST SEPARATELY IN ADDITION TO CODES FOR ECHOCARDIOGRAPHIC IMAGING); COMPLETE

93321

DOPPLER ECHOCARDIOGRAPHY, PULSED WAVE AND/OR CONTINUOUS WAVE WITH SPECTRAL DISPLAY (LIST SEPARATELY IN ADDITION TO CODES FOR ECHOCARDIOGRAPHIC IMAGING); FOLLOW-UP OR LIMITED STUDY (LIST SEPARATELY IN ADDITION TO CODES FOR ECHOCARDIOGRAPHIC IMAGING)

93325

DOPPLER ECHOCARDIOGRAPHY COLOR FLOW VELOCITY MAPPING (LIST SEPARATELY IN ADDITION TO CODES FOR ECHOCARDIOGRAPHY)

A9700

SUPPLY OF INJECTABLE CONTRAST MATERIAL FOR USE IN ECHOCARDIOGRAPHY, PER STUDY

Q9955

INJECTION, PERFLEXANE LIPID MICROSPHERES, PER ML

Q9956

INJECTION, OCTAFLUOROPROPANE MICROSPHERES, PER ML

Q9957

INJECTION, PERFLUTREN LIPID MICROSPHERES, PER ML

Hospitals billing under OPPS are instructed to bill for echocardiograms with contrast or without contrast, followed by contrast studies using the applicable HCPCS code(s) below. They should also report the appropriate units of HCPCS codes for the contrast agents used in the performance of the echocardiograms.

C8925

TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, REAL TIME WITH IMAGE DOCUMENTATION (2D) (WITH OR WITHOUT M-MODE RECORDING); INCLUDING PROBE PLACEMENT, IMAGE ACQUISITION, INTERPRETATION AND REPORT

C8926

TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, FOR CONGENITAL CARDIAC ANOMALIES; INCLUDING PROBE PLACEMENT, IMAGE ACQUISITION, INTERPRETATION AND REPORT

C8927

TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, FOR MONITORING PURPOSES, INCLUDING PROBE PLACEMENT, REAL TIME 2-DIMENSIONAL IMAGE ACQUISITION AND INTERPRETATION LEADING TO ONGOING (CONTINUOUS) ASSESSMENT OF (DYNAMICALLY CHANGING) CARDIAC PUMPING FUNCTION AND TO THERAPEUTIC MEASURES ON AN IMMEDIATE TIME BASIS

 

ICD-9 Codes that Support Medical Necessity

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-9-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

 

038.0

STREPTOCOCCAL SEPTICEMIA

038.10 - 038.11

STAPHYLOCOCCAL SEPTICEMIA UNSPECIFIED - STAPHYLOCOCCUS AUREUS SEPTICEMIA

038.19

OTHER STAPHYLOCOCCAL SEPTICEMIA

038.2

PNEUMOCOCCAL SEPTICEMIA

038.3

SEPTICEMIA DUE TO ANAEROBES

038.40 - 038.44

SEPTICEMIA DUE TO GRAM-NEGATIVE ORGANISM UNSPECIFIED - SEPTICEMIA DUE TO SERRATIA

038.49

OTHER SEPTICEMIA DUE TO GRAM-NEGATIVE ORGANISMS

038.8 - 038.9

OTHER SPECIFIED SEPTICEMIAS - UNSPECIFIED SEPTICEMIA

164.1

MALIGNANT NEOPLASM OF HEART

198.89

SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES

212.7

BENIGN NEOPLASM OF HEART

238.8

NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER SPECIFIED SITES

239.8

NEOPLASM OF UNSPECIFIED NATURE OF OTHER SPECIFIED SITES

276.50 - 276.52

VOLUME DEPLETION, UNSPECIFIED - HYPOVOLEMIA

276.6

FLUID OVERLOAD DISORDER

391.0 - 391.2

ACUTE RHEUMATIC PERICARDITIS - ACUTE RHEUMATIC MYOCARDITIS

392.0

RHEUMATIC CHOREA WITH HEART INVOLVEMENT

394.0 - 394.2

MITRAL STENOSIS - MITRAL STENOSIS WITH INSUFFICIENCY

395.0 - 395.2

RHEUMATIC AORTIC STENOSIS - RHEUMATIC AORTIC STENOSIS WITH INSUFFICIENCY

395.9

OTHER AND UNSPECIFIED RHEUMATIC AORTIC DISEASES

396.0 - 396.3

MITRAL VALVE STENOSIS AND AORTIC VALVE STENOSIS - MITRAL VALVE INSUFFICIENCY AND AORTIC VALVE INSUFFICIENCY

396.8

MULTIPLE INVOLVEMENT OF MITRAL AND AORTIC VALVES

397.0 - 397.1

DISEASES OF TRICUSPID VALVE - RHEUMATIC DISEASES OF PULMONARY VALVE

397.9

RHEUMATIC DISEASES OF ENDOCARDIUM VALVE UNSPECIFIED

398.0

RHEUMATIC MYOCARDITIS

398.90

RHEUMATIC HEART DISEASE UNSPECIFIED

414.10 - 414.11

ANEURYSM OF HEART (WALL) - ANEURYSM OF CORONARY VESSELS

414.19

OTHER ANEURYSM OF HEART

414.2

CHRONIC TOTAL OCCLUSION OF CORONARY ARTERY

415.0

ACUTE COR PULMONALE

415.11

IATROGENIC PULMONARY EMBOLISM AND INFARCTION

415.12

SEPTIC PULMONARY EMBOLISM

415.19

OTHER PULMONARY EMBOLISM AND INFARCTION

417.0

ARTERIOVENOUS FISTULA OF PULMONARY VESSELS

417.1

ANEURYSM OF PULMONARY ARTERY

421.0

ACUTE AND SUBACUTE BACTERIAL ENDOCARDITIS

421.1

ACUTE AND SUBACUTE INFECTIVE ENDOCARDITIS IN DISEASES CLASSIFIED ELSEWHERE

422.0

ACUTE MYOCARDITIS IN DISEASES CLASSIFIED ELSEWHERE

422.91

IDIOPATHIC MYOCARDITIS

422.92

SEPTIC MYOCARDITIS

423.0 - 423.9

HEMOPERICARDIUM - UNSPECIFIED DISEASE OF PERICARDIUM

424.0 - 424.3

MITRAL VALVE DISORDERS - PULMONARY VALVE DISORDERS

424.90 - 424.91

ENDOCARDITIS VALVE UNSPECIFIED UNSPECIFIED CAUSE - ENDOCARDITIS IN DISEASES CLASSIFIED ELSEWHERE

425.0 - 425.5

ENDOMYOCARDIAL FIBROSIS - ALCOHOLIC CARDIOMYOPATHY

425.7 - 425.9

NUTRITIONAL AND METABOLIC CARDIOMYOPATHY - SECONDARY CARDIOMYOPATHY UNSPECIFIED

427.31 - 427.32

ATRIAL FIBRILLATION - ATRIAL FLUTTER

429.0

MYOCARDITIS UNSPECIFIED

429.3

CARDIOMEGALY

429.4

FUNCTIONAL DISTURBANCES FOLLOWING CARDIAC SURGERY

429.5

RUPTURE OF CHORDAE TENDINEAE

429.6

RUPTURE OF PAPILLARY MUSCLE

429.71

CERTAIN SEQUELAE OF MYOCARDIAL INFARCTION NOT ELSEWHERE CLASSIFIED ACQUIRED CARDIAC SEPTAL DEFECT

429.81

OTHER DISORDERS OF PAPILLARY MUSCLE

429.83

TAKOTSUBO SYNDROME

435.0 - 435.3

BASILAR ARTERY SYNDROME - VERTEBROBASILAR ARTERY SYNDROME

435.8 - 435.9

OTHER SPECIFIED TRANSIENT CEREBRAL ISCHEMIAS - UNSPECIFIED TRANSIENT CEREBRAL ISCHEMIA

436

ACUTE BUT ILL-DEFINED CEREBROVASCULAR DISEASE

440.0

ATHEROSCLEROSIS OF AORTA

441.01

DISSECTION OF AORTA THORACIC

441.03

DISSECTION OF AORTA THORACOABDOMINAL

441.1

THORACIC ANEURYSM RUPTURED

441.2

THORACIC ANEURYSM WITHOUT RUPTURE

441.6

THORACOABDOMINAL ANEURYSM RUPTURED

441.7

THORACOABDOMINAL ANEURYSM WITHOUT RUPTURE

444.0

EMBOLISM AND THROMBOSIS OF ABDOMINAL AORTA

444.1

EMBOLISM AND THROMBOSIS OF THORACIC AORTA

444.21 - 444.22

ARTERIAL EMBOLISM AND THROMBOSIS OF UPPER EXTREMITY - ARTERIAL EMBOLISM AND THROMBOSIS OF LOWER EXTREMITY

444.81

EMBOLISM AND THROMBOSIS OF ILIAC ARTERY

444.89

EMBOLISM AND THROMBOSIS OF OTHER ARTERY

444.9

EMBOLISM AND THROMBOSIS OF UNSPECIFIED ARTERY

449

SEPTIC ARTERIAL EMBOLISM

458.8

OTHER SPECIFIED HYPOTENSION

458.9

HYPOTENSION UNSPECIFIED

459.2

COMPRESSION OF VEIN

459.30

CHRONIC VENOUS HYPERTENSION WITHOUT COMPLICATIONS

459.39

CHRONIC VENOUS HYPERTENSION WITH OTHER COMPLICATION

745.10 - 745.12

COMPLETE TRANSPOSITION OF GREAT VESSELS - CORRECTED TRANSPOSITION OF GREAT VESSELS

745.19

OTHER TRANSPOSITION OF GREAT VESSELS

745.2

TETRALOGY OF FALLOT

745.3

COMMON VENTRICLE

745.4

VENTRICULAR SEPTAL DEFECT

745.5

OSTIUM SECUNDUM TYPE ATRIAL SEPTAL DEFECT

745.60 - 745.61

ENDOCARDIAL CUSHION DEFECT UNSPECIFIED TYPE - OSTIUM PRIMUM DEFECT

745.69

OTHER ENDOCARDIAL CUSHION DEFECTS

745.7

COR BILOCULARE

746.00 - 746.02

CONGENITAL PULMONARY VALVE ANOMALY UNSPECIFIED - STENOSIS OF PULMONARY VALVE CONGENITAL

746.09

OTHER CONGENITAL ANOMALIES OF PULMONARY VALVE

746.1

TRICUSPID ATRESIA AND STENOSIS CONGENITAL

746.2

EBSTEIN'S ANOMALY

746.3

CONGENITAL STENOSIS OF AORTIC VALVE

746.4

CONGENITAL INSUFFICIENCY OF AORTIC VALVE

746.5

CONGENITAL MITRAL STENOSIS

746.6

CONGENITAL MITRAL INSUFFICIENCY

746.7

HYPOPLASTIC LEFT HEART SYNDROME

746.81 - 746.85

SUBAORTIC STENOSIS CONGENITAL - CORONARY ARTERY ANOMALY CONGENITAL

747.0

PATENT DUCTUS ARTERIOSUS

747.41

TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION

747.42

PARTIAL ANOMALOUS PULMONARY VENOUS CONNECTION

780.6

FEVER

785.50

SHOCK UNSPECIFIED

785.51

CARDIOGENIC SHOCK

785.52

SEPTIC SHOCK

901.0

INJURY TO THORACIC AORTA

958.4

TRAUMATIC SHOCK

996.01

MECHANICAL COMPLICATION DUE TO CARDIAC PACEMAKER (ELECTRODE)

996.02

MECHANICAL COMPLICATION DUE TO HEART VALVE PROSTHESIS

996.61

INFECTION AND INFLAMMATORY REACTION DUE TO CARDIAC DEVICE IMPLANT AND GRAFT

996.71

OTHER COMPLICATIONS DUE TO HEART VALVE PROSTHESIS

996.72

OTHER COMPLICATIONS DUE TO OTHER CARDIAC DEVICE IMPLANT AND GRAFT

998.0

POSTOPERATIVE SHOCK NOT ELSEWHERE CLASSIFIED

998.51

INFECTED POSTOPERATIVE SEROMA

998.59

OTHER POSTOPERATIVE INFECTION

999.1

AIR EMBOLISM AS A COMPLICATION OF MEDICAL CARE NOT ELSEWHERE CLASSIFIED

V15.1

PERSONAL HISTORY OF SURGERY TO HEART AND GREAT VESSELS PRESENTING HAZARDS TO HEALTH

V42.1

HEART REPLACED BY TRANSPLANT

V42.6

LUNG REPLACED BY TRANSPLANT

V43.3

HEART VALVE REPLACED BY OTHER MEANS

V58.64

LONG-TERM (CURRENT) USE OF NONSTEROIDAL ANTI-INFLAMMATORIES

V58.65

LONG-TERM (CURRENT) USE OF STEROIDS

V58.69

LONG-TERM (CURRENT) USE OF OTHER MEDICATIONS

V59.8

DONORS OF OTHER SPECIFIED ORGAN OR TISSUE

V72.85*

OTHER SPECIFIED EXAMINATION

*Use this code, when performing a transesophageal echo, along with the primary diagnosis code from the Transthoracic Echocardiography LCD #L27536 to indicate this study is being performed because the results of the prior TTE were inconclusive.

Diagnoses that Support Medical Necessity

N/A

ICD-9 Codes that DO NOT Support Medical Necessity

All those not listed under the “ICD-9 Codes that Support Medical Necessity” section of this policy.

ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation

 

Diagnoses that DO NOT Support Medical Necessity

Conditions that are not listed in the "ICD-9-CM Codes that Support Medical Necessity" section of this policy.

General Information

Documentation Requirements

  1. All documentation must be maintained in the patient’s medical record and available to the contractor upon request.
  2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service(s)).  The record must include the physician or non-physician practitioner responsible for and providing the care of the patient.
  3. The submitted medical record should support the use of the selected ICD-9-CM code(s).  The submitted CPT/HCPCS code should describe the service performed.

Adequate documentation is essential for high quality patient care. There should be a permanent record of the echocardiogram and its interpretation included in the medical record. The interpretation should be a comprehensive report addressing the relevant clinical history and issues, comparative information (when available), and complete interpretive impression/findings. Images of all appropriate areas, both normal and abnormal, should be recorded. Variation from normal size should be accompanied by measurements.

Utilization Guidelines

In accordance with CMS Ruling 95-1 (V), utilization of these services should be consistent with locally acceptable standards of practice. 

Sources of Information and Basis for Decision

Other Contractor’s Policies (Highmark Medicare Services Pennsylvania Carrier and Highmark Medicare Services Maryland/Washington, D.C. Fiscal Intermediary, Louisiana, Virginia, Wisconsin, New York, Utah)

Model Local Medical Policy 1996

Highmark Medicare Services Contractor Medical Directors

 

Advisory Committee Meeting Notes

This policy does not reflect the sole opinion of the contractor or Contractor Medical Directors. Although the final decision rests with the contractor, this policy was developed in cooperation with advisory groups, which includes representatives from Cardiology.

CAC/IAC Distribution:  04/01/2008

Start Date of Comment Period

04/01/2008

End Date of Comment Period:

05/15/2008

Start Date of Notice Period

05/23/2008

Revision History

Revision History Number

L27535

Revision History Explanation

DatePolicy #Description

08/01/2008

L27535

LCD effective 08/01/2008 for DC Part A, Maryland Part A, and Pennsylvania Part A. LCD is now effective for DC Part A and DCMA Part B; Maryland Part A and Maryland Part B; Pennsylvania Part A; and Delaware Part B.

05/23/2008

L27535

Original LCD posted for notice. LCD to become effective 07/11/2008 for Maryland Part B, DCMA Part B and Delaware Part B.

04/01/2008

Draft J12-D49

Original LCD posted for comment.

Last Reviewed On

07/31/2008

Related Documents

This LCD has no Related Documents. 

LCD Attachments

There are no attachments for this LCD.

© 2005-2008. All rights are reserved.